Johnson & Johnson

Latest Headlines

Latest Headlines

Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push

For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.

J&J and ViiV's long-acting HIV treatment stacks up to daily pills in Phase II

A new semimonthly treatment from Johnson & Johnson and ViiV Healthcare tamped down HIV as well as daily therapy in a midstage trial, promising a more convenient option for patients.

J&J's Ethicon partners with Fogarty Institute to back next-gen device innovation

Nonprofit incubator Fogarty Institute for Innovation is partnering with Johnson & Johnson's surgical device specialist Ethicon to develop next generation medical devices. Ethicon will sponsor the Institute to support its educational programs as well as offer leadership and mentorship to its resident med tech innovators.

How much can J&J make of Yondelis' long-sought FDA approval?

After years of setbacks, Johnson & Johnson's Yondelis finally has its shot at some U.S. sales. The drug won its sought-after FDA approval Friday--not in ovarian cancer as previously hoped, but as a treatment for soft-tissue sarcoma, which otherwise has few treatment options. 

J&J device heads say the new med tech innovation model calls for more external partnerships

Johnson & Johnson is shaking up its med tech innovation model. Its sprawling medical device unit had a quarterly operational sales increase of just 1.3% to $6.1 billion when adjusting for divestitures and foreign currency fluctuations. Add a negative currency impact to the equation, and the growth rate was-7.3%.

J&J's Yondelis finally captures FDA nod, but path to big sales could be steep

Once upon a time, analysts thought the cancer-fighting prospect Yondelis could hit $1 billion in sales by 2010. But that timetable went poof years ago--and so did the forecast--as the drug failed to win the FDA's approval, and eventually ended up in a partnership between Spain's Zeltia and Johnson & Johnson's Janssen unit.

J&J's cancer drug finally wins FDA approval after 6 years of delay

About 6 years after its first rejection, Johnson & Johnson's long-delayed cancer drug Yondelis won FDA approval to treat soft tissue sarcomas, finding success in its third go round.

J&J inks deal to access Nuevolution's informatics-enabled discovery platform

Johnson & Johnson has added another company to its ever-growing network of third-party drug discovery allies. The latest deal sees J&J subsidiary Janssen Biotech follow GlaxoSmithKline, Merck, Novartis and others by hooking up with Nuevolution to get a look at its drug discovery platform.

J&J chalks up a win in first Tylenol liver-damage case to go to trial

Johnson & Johnson scored a victory in the first case to go to trial over claims that its blockbuster painkiller Tylenol causes liver damage and its dosing doesn't adequately account for the risk. A New Jersey jury ruled that the plaintiff did not prove that she took the painkiller.

J&J's Stelara, under fire in psoriasis, racks up data for new Crohn's indication

​Johnson & Johnson's Stelara may be under fire in psoriasis. But the New Jersey drugmaker has new data suggesting it'll be able to score elsewhere.